Protected: Conquering the Whirlwind
There is no excerpt because this is a protected post.
The Future of Big Pharma: Preventative Medicine?
Rising healthcare costs in the United States have caused government, corporate, and association leaders to look for ways to make our healthcare system more efficient. Insurance provider and Affordable Care Act plans both provide for preventative care in order to keep long term costs down for the patient and the
Wait, the Doctor-Patient Conversation?
In pharma marketing, messaging and targeting are everything. The most appropriate words delivered to a carefully selected group of healthcare professionals leads to patients getting the best treatments. Or does it? When listening to patients and physicians separately, we often get different answers. Asking a patient how a diagnosis was delivered
Simplifying Oncology: Incorporate KOLS
The last decade has brought a variety of innovative cancer treatment options to the market. A 2009 study conducted by PhRMA compiled a list of 129 medications in development to treat Leukemia, 122 to treat lung cancer, and 106 to treat breast cancer[1]. The number of oncology patients has steadily grown
Your Most Important Role at Association Meetings
Association season is here. It’s that time of year to pack your bags and get away for a few days to meet up with old friends, see the competition’s abstracts, learn about the ground-breaking science, see the proof behind your product’s science, and hear about the late-breaking clinical trials. There is
4 Simple Tips for Smart Advisory Boards
At the heart of your advisory board, you should find engaging, and even impassioned, discussions by Key Opinion Leaders (KOLs). They want to help you make a difference. Planning for effective communication within your advisory board will allow for a higher impact advisory board so you can glean more insights
Can Your Brand Survive Without Paying Speakers?
What a move by GlaxoSmithKline, they are no longer paying speakers for speaker programs beginning in 2016. I have attended many speaker programs throughout my career. They’re usually a gathering of local clinicians, led by a Key Opinion Leader (KOL) who can help elucidate some important information, and are facilitated
Speaker Portals: Cut Costs and Build Relationships
Historically, pharmaceutical companies have depended on disparate systems for speakers and consultants. Contracting and management of these HCPs, whose roles frequently overlap and are difficult to track. With Sunshine Act reporting now required, pharmaceutical companies need to have a singular, consolidated view of their engagement with contracted HCPs. The pharmaceutical leaders
